The ITC case is really one-of-a-kind - no way to predict what will happen. More details here: https://www.raps.org/news-and-articles/news-articles/2018/7/update-on-the-amarin-itc-case-and-the-issues-at-st If they lose with the ITC, they have other venues (patent infringement for example) where they could proceed. Be very surprised if they don't raise money here. On pricing, let's wait for the detailed data to better understand the effect of the drug. Peter